Fig. 3 | Signal Transduction and Targeted Therapy

Fig. 3

From: Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study

Fig. 3

Cell DIVE multiplexed imaging revealed differences in cell composition of biopsy samples from RCC patients before neoadjuvant therapy. a Bar chart showed the immune cell composition of RCC patients (n = 13) with different TT responses; b Bar graphs showed the difference between representative T cells in R (n = 7) and NR (n = 6) patients; c Representative immunofluorescence plots showed the difference in the expression of T cytotoxic PD-1/+ cells between R and NR patients. Scale bars, 100 μm

Back to article page